/PRNewswire/ Novadip Biosciences SA ("Novadip" or "the Company"), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue.
Second patient scheduled for implantation with NVD-003 in June 2023 Pivotal trial is expected to begin in the second half of 2024 Novadip Biosciences SA ("Novadip" or "the Company"), a clinical-stage